The purpose of this study is to evaluate clinical safety issues pertaining to flupenthixol, to cocaine, and to their interaction, and to determine how pretreatment with flupenthixol modifies the subjective as well as physiological effects of cocaine. Taken together, these relatively D-1 selective agents can help determine the extent to which DA-1 binding affects the reinforcing effects of stimulants.

Condition	Treatment or Intervention	Phase
Cocaine-Related Disorders	Drug: Flupenthixol	Phase I

Ages Eligible for Study:  21 Years   -   50 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

M/F, ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

California
      Friends Research Institute, Los Angeles,  California,  90025,  United States

Study chairs or principal investigators

Walter Ling, M.D.,  Principal Investigator,  Friends Research Institute   

Study ID Numbers:  NIDA-3-0010-14; Y01-3-0010-14
Record last reviewed:  December 2002
Last Updated:  December 3, 2004
Record first received:  September 20, 1999
ClinicalTrials.gov Identifier:  NCT00000349
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08